{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:35:36Z","timestamp":1794270936790,"version":"4.9.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-63696-5","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:05:34Z","timestamp":1759248334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4821-6495","authenticated-orcid":false,"given":"Dominic","family":"Schmid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Sobottka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Manzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Tr\u00fcb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4004-3473","authenticated-orcid":false,"given":"Katharina","family":"Leonards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Herzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwaseun Rume-Abiola","family":"Oyewole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Jermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2265-6559","authenticated-orcid":false,"given":"Stefanie","family":"Hayoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spasenija","family":"Savic Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Tochtermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Natoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos","family":"Pless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Bettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fr\u00fch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6652-1947","authenticated-orcid":false,"given":"Laetitia A.","family":"Mauti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8831-1564","authenticated-orcid":false,"given":"Christian","family":"Britschgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-7143","authenticated-orcid":false,"given":"Solange","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1773-5436","authenticated-orcid":false,"given":"Adrian F.","family":"Ochsenbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Dieter","family":"Janthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Waibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-1088","authenticated-orcid":false,"given":"Nicolas","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Froesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6590-1203","authenticated-orcid":false,"given":"Martin","family":"Buess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bohanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8705-4279","authenticated-orcid":false,"given":"Michel","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7849-3958","authenticated-orcid":false,"given":"Ilaria","family":"Alborelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1304-9340","authenticated-orcid":false,"given":"Sacha I.","family":"Rothschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor Hendrik","family":"Koelzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1933-8178","authenticated-orcid":false,"given":"Alfred","family":"Zippelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"63696_CR1","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7\u201330 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"63696_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw, P. et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J. Thorac. Oncol. 11, 39\u201351 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"63696_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.5306\/wjco.v13.i5.314","volume":"13","author":"C Aguado","year":"2022","unstructured":"Aguado, C. et al. Neoadjuvant treatment in non-small cell lung cancer: new perspectives with the incorporation of immunotherapy. World J. Clin. Oncol. 13, 314 (2022).","journal-title":"World J. Clin. Oncol."},{"key":"63696_CR4","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(15)60294-X","volume":"386","author":"M Pless","year":"2015","unstructured":"Pless, M. et al. Induction chemoradiation in stage IIIA\/N2 non-small-cell lung cancer: a phase 3 randomised trial.  Lancet 386, 1049\u20131056 (2015).","journal-title":"Lancet"},{"key":"63696_CR5","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1200\/JCO.2003.11.040","volume":"21","author":"DC Betticher","year":"2003","unstructured":"Betticher, D. C. et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J. Clin. Oncol. 21, 1752\u20131759 (2003).","journal-title":"J. Clin. Oncol."},{"key":"63696_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jtho.2018.09.011","volume":"14","author":"M Fr\u00fch","year":"2019","unstructured":"Fr\u00fch, M. et al. Multimodal treatment in operable stage III NSCLC: a pooled analysis on long-term results of three SAKK trials (SAKK 16\/96, 16\/00, and 16\/01). J. Thorac. Oncol. 14, 115\u2013123 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"63696_CR7","unstructured":"Burdett, S. et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev. 2015, CD011430 (2015)."},{"key":"63696_CR8","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","volume":"383","author":"NSCLC Meta-analysis Collaborative Group","year":"2014","unstructured":"NSCLC Meta-analysis Collaborative Group Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 383, 1561\u20131571 (2014).","journal-title":"Lancet"},{"key":"63696_CR9","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","volume":"25","author":"DB Doroshow","year":"2019","unstructured":"Doroshow, D. B. et al. Immunotherapy in non-small cell lung cancer: facts and hopes. Clin. Cancer Res. 25, 4592\u20134602 (2019).","journal-title":"Clin. Cancer Res."},{"key":"63696_CR10","doi-asserted-by":"crossref","unstructured":"Provencio, M. et al. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). J. Clin. Oncol. 40, 2924\u20132933 (2022).","DOI":"10.1200\/JCO.21.02660"},{"key":"63696_CR11","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 386, 1973\u20131985 (2022).","journal-title":"N. Engl. J. Med."},{"key":"63696_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee, H. et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N. Engl. J. Med. 389, 491\u2013503 (2023).","journal-title":"N. Engl. J. Med."},{"key":"63696_CR13","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach, J. V. et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N. Engl. J. Med. 389, 1672\u20131684 (2023).","journal-title":"N. Engl. J. Med."},{"key":"63696_CR14","doi-asserted-by":"publisher","first-page":"425126","DOI":"10.1200\/JCO.2023.41.36_suppl.425126","volume":"41","author":"S Lu","year":"2023","unstructured":"Lu, S. et al. Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II\/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study. J. Clin. Oncol. 41, 425126\u2013425126 (2023).","journal-title":"J. Clin. Oncol."},{"key":"63696_CR15","doi-asserted-by":"publisher","first-page":"S1295","DOI":"10.1016\/j.annonc.2023.10.050","volume":"34","author":"T Cascone","year":"2023","unstructured":"Cascone, T. et al. LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II\u2013IIIb NSCLC. Ann. Oncol. 34, S1295 (2023).","journal-title":"Ann. Oncol."},{"key":"63696_CR16","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.21.00276","volume":"39","author":"SI Rothschild","year":"2021","unstructured":"Rothschild, S. I. et al. SAKK 16\/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small-cell lung cancer\u2014a multicenter single-arm phase II trial. J. Clin. Oncol. 39, 2872\u20132880 (2021).","journal-title":"J. Clin. Oncol."},{"key":"63696_CR17","doi-asserted-by":"publisher","first-page":"590","DOI":"10.21037\/tlcr-20-573","volume":"10","author":"M Pradhan","year":"2021","unstructured":"Pradhan, M., Chocry, M., Gibbons, D. L., Sepesi, B. & Cascone, T. Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer. Transl. Lung Cancer Res. 10, 590 (2021).","journal-title":"Transl. Lung Cancer Res."},{"key":"63696_CR18","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1200\/JCO.21.02660","volume":"40","author":"M Provencio","year":"2022","unstructured":"Provencio, M. et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-small-cell lung cancer (NADIM phase II trial). J. Clin. Oncol. 40, 2924 (2022).","journal-title":"J. Clin. Oncol."},{"key":"63696_CR19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ccell.2021.01.004","volume":"39","author":"A Irmisch","year":"2021","unstructured":"Irmisch, A. et al. The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. Cancer Cell 39, 288\u2013293 (2021).","journal-title":"Cancer Cell"},{"key":"63696_CR20","doi-asserted-by":"publisher","first-page":"748","DOI":"10.21037\/tlcr.2019.10.09","volume":"8","author":"Y Sun","year":"2019","unstructured":"Sun, Y. et al. Characterization of PD-L1 protein expression and CD8+ tumor-infiltrating lymphocyte density, and their associations with clinical outcome in small-cell lung cancer. Transl. Lung Cancer Res. 8, 748\u2013759 (2019).","journal-title":"Transl. Lung Cancer Res."},{"key":"63696_CR21","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251\u20131259 (2019).","journal-title":"Nat. Med."},{"key":"63696_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ejca.2023.03.010","volume":"186","author":"R Nie","year":"2023","unstructured":"Nie, R. et al. Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials. Eur. J. Cancer 186, 211\u2013221 (2023).","journal-title":"Eur. J. Cancer"},{"key":"63696_CR23","unstructured":"Amgad, M. et al. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer 6. 16 (2020)."},{"key":"63696_CR24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILS) in breast cancer: Recommendations by an International TILS Working Group 2014. Ann. Oncol. 26, 259\u2013271 (2015).\u00a0","journal-title":"Ann. Oncol."},{"key":"63696_CR25","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/s41374-021-00653-y","volume":"101","author":"B Sobottka","year":"2021","unstructured":"Sobottka, B. et al. Establishing standardized immune phenotyping of metastatic melanoma by digital pathology. Lab. Investig. 101, 1561\u20131570 (2021).","journal-title":"Lab. Investig."},{"key":"63696_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307\u2013325 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"63696_CR27","doi-asserted-by":"publisher","first-page":"eabf9419","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher, T. N. & Thommen, D. S. Tertiary lymphoid structures in cancer. Science 375, eabf9419 (2022).","journal-title":"Science"},{"key":"63696_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1890\/13-0133.1","volume":"84","author":"A Chao","year":"2014","unstructured":"Chao, A. et al. Rarefaction and extrapolation with Hill numbers: a framework for sampling and estimation in species diversity studies. Ecol. Monogr. 84, 45\u201367 (2014).","journal-title":"Ecol. Monogr."},{"key":"63696_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14273-0","volume":"11","author":"A Reuben","year":"2020","unstructured":"Reuben, A. et al. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat. Commun. 11, 603 (2020).","journal-title":"Nat. Commun."},{"key":"63696_CR30","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-18-1127","volume":"79","author":"V Anagnostou","year":"2019","unstructured":"Anagnostou, V. et al. Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. Cancer Res.79, 1214\u20131225 (2019).","journal-title":"Cancer Res."},{"key":"63696_CR31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2326-6066.CIR-19-0398","volume":"8","author":"J Han","year":"2020","unstructured":"Han, J. et al. TCR repertoire diversity of peripheral PD-1\u2009+\u2009CD8\u2009+\u2009T cells predicts clinical outcomes after immunotherapy in patients with non\u2013small cell lung cancer. Cancer Immunol. Res. 8, 146\u2013154 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"63696_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-015-0070-4","volume":"3","author":"MA Postow","year":"2015","unstructured":"Postow, M. A. et al. Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. J. Immunother. Cancer 3, 1\u20135 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"63696_CR33","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3389\/fimmu.2019.01336","volume":"10","author":"A Arakawa","year":"2019","unstructured":"Arakawa, A. et al. Clonality of CD4+ blood T cells predicts longer survival with CTLA4 or PD-1 checkpoint inhibition in advanced melanoma. Front. Immunol. 10, 1336 (2019).","journal-title":"Front. Immunol."},{"key":"63696_CR34","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","volume":"17","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti, B. et al. Diminished efficacy of programmed death-(Ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status. J. Thorac. Oncol. 17, 399\u2013410 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"63696_CR35","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1158\/2326-6066.CIR-20-0270","volume":"8","author":"KE Kortekaas","year":"2020","unstructured":"Kortekaas, K. E. et al. CD39 identifies the CD4+ tumor-specific T-cell population in human cancer. Cancer Immunol. Res. 8, 1311\u20131321 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"63696_CR36","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","volume":"584","author":"ST Ferris","year":"2020","unstructured":"Ferris, S. T. et al. cDC1 prime and are licensed by CD4\u2009+\u2009T cells to induce anti-tumour immunity. Nature 584, 624\u2013629 (2020).","journal-title":"Nature"},{"key":"63696_CR37","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41591-018-0096-5","volume":"24","author":"D Lambrechts","year":"2018","unstructured":"Lambrechts, D. et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat. Med. 24, 1277\u20131289 (2018).","journal-title":"Nat. Med."},{"key":"63696_CR38","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1002\/cam4.2113","volume":"8","author":"Q Song","year":"2019","unstructured":"Song, Q. et al. Dissecting intratumoral myeloid cell plasticity by single-cell RNA-seq. Cancer Med. 8, 3072\u20133085 (2019).","journal-title":"Cancer Med."},{"key":"63696_CR39","doi-asserted-by":"crossref","unstructured":"Wu, F. et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat. Commun. 12, 2540 (2021).","DOI":"10.1038\/s41467-021-22801-0"},{"key":"63696_CR40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu, B. et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat. Cancer 3, 108\u2013121 (2022).","journal-title":"Nat. Cancer"},{"key":"63696_CR41","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41571-021-00501-4","volume":"18","author":"JE Chaft","year":"2021","unstructured":"Chaft, J. E. et al. Evolution of systemic therapy for stages I\u2013III non-metastatic non-small-cell lung cancer. Nat. Rev. Clin. Oncol. 18, 547\u2013557 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"63696_CR42","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","volume":"6","author":"J Liu","year":"2016","unstructured":"Liu, J. et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 6, 1382\u20131399 (2016).","journal-title":"Cancer Discov."},{"key":"63696_CR43","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1158\/1538-7445.AM2018-1719","volume":"78","author":"T Cascone","year":"2018","unstructured":"Cascone, T. et al. Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer. Cancer Res. 78, 1719 (2018).","journal-title":"Cancer Res."},{"key":"63696_CR44","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1158\/1078-0432.CCR-23-1316","volume":"30","author":"A Mariniello","year":"2024","unstructured":"Mariniello, A. et al. Platinum-based chemotherapy attenuates the effector response of CD8 T cells to concomitant PD-1 blockade. Clin. Cancer Res. 30, 1833\u20131845 (2024).","journal-title":"Clin. Cancer Res."},{"key":"63696_CR45","doi-asserted-by":"crossref","unstructured":"Chaft J. E. et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med. 28, 2155\u20132161 (2022).","DOI":"10.1038\/s41591-022-01962-5"},{"key":"63696_CR46","doi-asserted-by":"crossref","unstructured":"Reuss, J. E. et al. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J. Immunother. Cancer 8, (2020).","DOI":"10.1136\/jitc-2020-001282"},{"key":"63696_CR47","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1200\/EDBK_358995","volume":"42","author":"M Provencio","year":"2022","unstructured":"Provencio, M., Calvo, V., Romero, A., Spicer, J. D. & Cruz-Berm\u00fadez, A. Treatment sequencing in resectable lung cancer: the good and the bad of adjuvant versus neoadjuvant therapy. Am. Soc. Clin. Oncol. Educ. Book 42, 711\u2013728 (2022).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"63696_CR48","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/1078-0432.CCR-20-1420","volume":"27","author":"R Ferrara","year":"2021","unstructured":"Ferrara, R. et al. Circulating T-cell immunosenescence in patients with advanced non-small cell lung cancer treated with single-agent PD-1\/PD-L1 inhibitors or platinum-based chemotherapy. Clin. Cancer Res. 27, 492\u2013503 (2021).","journal-title":"Clin. Cancer Res."},{"key":"63696_CR49","doi-asserted-by":"crossref","unstructured":"An, H. J., Chon, H. J. & Kim, C. Peripheral blood-based biomarkers for immune checkpoint inhibitors. Int. J. Mol. Sci. 22, (2021).","DOI":"10.3390\/ijms22179414"},{"key":"63696_CR50","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","volume":"595","author":"KO Dixon","year":"2021","unstructured":"Dixon, K. O. et al. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. Nature 595, 101\u2013106 (2021).","journal-title":"Nature"},{"key":"63696_CR51","doi-asserted-by":"crossref","unstructured":"Saleh, Toor, Khalaf & Elkord. Breast cancer cells and PD-1\/PD-L1 blockade upregulate the expression of PD-1, CTLA-4, TIM-3 and LAG-3 immune checkpoints in CD4\u2009+\u2009T Cells. Vaccines 7, 149 (2019).","DOI":"10.3390\/vaccines7040149"},{"key":"63696_CR52","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.1158\/1078-0432.CCR-18-1038","volume":"24","author":"A Oweida","year":"2018","unstructured":"Oweida, A. et al. Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-cell infiltration. Clin. Cancer Res. 24, 5368\u20135380 (2018).","journal-title":"Clin. Cancer Res."},{"key":"63696_CR53","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.3390\/cancers11091400","volume":"11","author":"N-Y Sun","year":"2019","unstructured":"Sun, N.-Y. et al. Blockade of PD-L1 enhances cancer immunotherapy by regulating dendritic cell maturation and macrophage polarization. Cancers 11, 1400 (2019).","journal-title":"Cancers"},{"key":"63696_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.06.020","author":"G Dolton","year":"2023","unstructured":"Dolton, G. et al. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell https:\/\/doi.org\/10.1016\/j.cell.2023.06.020 (2023).","journal-title":"Cell"},{"key":"63696_CR55","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1158\/1078-0432.CCR-19-2931","volume":"26","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. Compartmental analysis of T-cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. Clin. Cancer Res. 26, 1327\u20131337 (2020).","journal-title":"Clin. Cancer Res."},{"key":"63696_CR56","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41591-022-02189-0","volume":"29","author":"T Cascone","year":"2023","unstructured":"Cascone, T. et al. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat. Med. 29, 593\u2013604 (2023).","journal-title":"Nat. Med."},{"key":"63696_CR57","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1158\/1078-0432.CCR-21-1200","volume":"27","author":"M Casarrubios","year":"2021","unstructured":"Casarrubios, M. et al. Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy. Clin. Cancer Res. 27, 5878\u20135890 (2021).","journal-title":"Clin. Cancer Res."},{"key":"63696_CR58","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13045-021-01103-4","volume":"14","author":"T Fu","year":"2021","unstructured":"Fu, T. et al. Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. J. Hematol. Oncol. 14, 98 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"63696_CR59","doi-asserted-by":"publisher","first-page":"2206725","DOI":"10.1080\/2162402X.2023.2206725","volume":"12","author":"A Sandstr\u00f6m Gerdtsson","year":"2023","unstructured":"Sandstr\u00f6m Gerdtsson, A. et al. Phenotypic characterization of spatial immune infiltration niches in non-small cell lung cancer. Oncoimmunology 12, 2206725 (2023).","journal-title":"Oncoimmunology"},{"key":"63696_CR60","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"63696_CR61","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"63696_CR62","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556\u2013560 (2020).","journal-title":"Nature"},{"key":"63696_CR63","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","volume":"24","author":"DS Thommen","year":"2018","unstructured":"Thommen, D. S. et al. A transcriptionally and functionally distinct PD-1\u2009+\u2009CD8\u2009+\u2009T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat. Med. 24, 994\u20131004 (2018).","journal-title":"Nat. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63696-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63696-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63696-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T17:03:46Z","timestamp":1759251826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63696-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["63696"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-63696-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4144547\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"28 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.S., B.S., MaMa, P.H., O.R.O., S.H., G.T., A.B., C.W., M.B., M.G. and I.A. do not report competing interests. M.T.: Numab Therapeutics (employment and equity or stocks). K.L.: LNS Laboratoire national de sant\u00e9 (employment). P.J.: Thermo Fisher Scientific (employment). S.S.P.: Novartis (honoraria), Diaceutics Ireland Limited, Merck (Schweiz) AG, AstraZeneca AG (consulting or advisory role). M.N.: AstraZeneca PLC (employment and equity or stocks). M.P.: Janssen-Cilag (honoraria), AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eisai Europe, MSD Oncology, Novartis, Pfizer\/EMD Serono, Roche, Takeda, Merck Serono (consulting or advisory role), Takeda (expert testimony), Vifor Pharma, Bristol Myers Squibb, Boehringer Ingelheim, AstraZeneca (travel, accommodation, expenses). M.F.: BMS, AstraZeneca, MSD, Takeda, Roche, Lilly (consulting or advisory role), Pfizer (speakers\u2019 bureau), BMS, AstraZeneca (research funding) LAM: Takeda, Roche, AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Pfizer (consulting or advisory role), Takeda, Bristol Myers Squibb, Merck, Roche, AstraZeneca (travel, accommodation, expenses). C.B.: AstraZeneca, Pfizer, Roche, Takeda, Janssen-Cilag, Boehringer Ingelheim (consulting or advisory role), AstraZeneca, Takeda (travel, accommodation, expenses). S.P.: Roche, Bristol Myers Squibb, Novartis, Pfizer, MSD, AstraZeneca, Takeda, Illumina, Medscape (honoraria), Roche\/Genentech, Novartis, Bristol Myers Squibb, Pfizer, MSD, Amgen, AstraZeneca, Janssen, Regeneron, Merck Serono, Boehringer Ingelheim, Takeda, Lilly, AbbVie, Bayer, Biocartis, Debiopharm Group, Illumina, PharmaMar, Sanofi, Seattle Genetics, Blueprint Medicines, Daiichi Sankyo, Incyte, Bioinvent, Clovis Oncology, Vaccibody, Phosplatin Therapeutics (consulting or advisory role), Roche, BMS, MSD, Amgen, Lilly, AstraZeneca, Pfizer, Illumina, Merck Serono, Novartis, Biodesix, Boehringer Ingelheim, Iovance Biotherapeutics, Phosplatin Therapeutics (research funding), Roche, Bristol Myers Squibb, MSD, Sanofi, Incyte (travel, accommodation, expenses). MiMa: Roche, AstraZeneca, Takeda, BMS, MSD Oncology (consulting or advisory role), Pfizer, Roche, Takeda (travel, accommodation, expenses). A.F.O.: Tolremo (consulting or advisory role), argenx (research funding) W.D.J.: Roche, Takeda, MSD, Novartis (consulting or advisory role). N.M.: MaxVAX SA (stock or equity, research funding). P.F.: Pfizer, Takeda, Roche, Boehringer Ingelheim, AstraZeneca, Novartis, Bayer (consulting or advisory role). P.B.: MSD, Bayer (consulting or advisory role), Janssen (travel, accommodation, expenses). S.R.: Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Eisai, Roche, Novartis, Merck Serono, MSD Oncology, Pfizer, Takeda, AbbVie (consulting or advisory role), Boehringer Ingelheim, AstraZeneca, Bristol Myers Squibb, Eisai, Merck Serono, AbbVie (research funding), Roche, AstraZeneca, Bristol Myers Squibb (expert testimony), Roche Pharma AG, Lilly, Bristol Myers Squibb, AstraZeneca, Merck Sharp & Dohme, Amgen (travel, accommodation, expenses). V.H.K.: Sharing Progress in Cancer Care, Indica Labs (invited speaker), Takeda (consulting or advisory role), Roche, IAG (research funding), patent applications on the assessment of cancer immunotherapy biomarkers by digital pathology and for the prediction of cancer recurrence risk and prediction of treatment efficacy using deep learning, unrelated to the current study. A.Z.: Roche, NBE Therapeutics, Engimmune (consulting or advisory role), Roche, Bright Peak Therapeutics, T3 Pharma (research funding).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8673"}}